Instalab
Login
How do your genes decide how caffeine affects your performance?
Why does caffeine help some people feel sharp and focused while others feel anxious or wired? Your response may depend on three genes, CYP1A2, AHR, and ADORA2A, that regulate how you metabolize and react to caffeine. Understanding your caffeine genetics may help you optimize performance, reduce side effects, and even lower your cardiovascular risk.
Instalab Research

Why Some People Thrive on Caffeine, And Others Crash

Caffeine isn’t a one-size-fits-all performance booster. While it enhances alertness, stamina, and strength in many people, others experience anxiety, jitters, or disrupted sleep. The difference may come down to your DNA.

Several genes shape how your body handles caffeine. Three stand out: - CYP1A2: Determines how fast you metabolize caffeine. - AHR: Controls how active your CYP1A2 enzyme is. - ADORA2A: Affects how sensitive your brain is to caffeine’s stimulant effects. Together, these genes explain why your daily coffee habit might be helping, or harming, your health and performance.

1. CYP1A2: Your Caffeine Breakdown Speed

The liver enzyme CYP1A2 metabolizes about 95% of the caffeine you consume. The gene that encodes this enzyme exists in multiple versions (called polymorphisms), and these influence how quickly caffeine is cleared from your body.

Two key SNPs (single nucleotide polymorphisms) in CYP1A2 are relevant:

  • rs762551 (also called -163C>A): If you have the AA genotype, you’re a fast metabolizer. AC and CC genotypes are slow metabolizers.
  • rs2472297: People with the T allele drink more coffee and may have more active caffeine metabolism than those with the C allele.

Fast metabolizers (AA) tend to experience performance-enhancing effects from caffeine (greater endurance, strength, and focus) without lingering side effects. Slow metabolizers (AC or CC) may feel overstimulated, anxious, or experience elevated blood pressure. Studies also show that slow metabolizers who consume over 2 cups of coffee daily have a higher risk of heart attack, while fast metabolizers may experience a protective effect.

2. AHR: The Master Switch for Caffeine Metabolism

CYP1A2 doesn’t work in isolation. It is regulated by another gene called AHR (aryl hydrocarbon receptor), which acts like a light switch: turning CYP1A2 on or off in response to environmental triggers, like caffeine.

People with the C allele of AHR rs4410790 are more likely to consume high amounts of caffeine and have stronger induction of the CYP1A2 enzyme.

Nearly 49% of the general population carries this C allele, with the highest prevalence in Asians (63%). In essence, AHR sets your caffeine “sensitivity dial.” If you carry this C allele, your system might be better equipped to ramp up caffeine metabolism in response to intake.

3. ADORA2A: The Gene Behind Caffeine Sensitivity and Anxiety

Caffeine works by blocking adenosine receptors in the brain, specifically A1 and A2a receptors. This prevents the feeling of drowsiness and increases dopamine release, enhancing alertness and mood. But not all brains respond the same way.

Variations in the ADORA2A gene, which encodes the A2a receptor, determine how sensitive you are to caffeine’s effects:

  • Individuals with the C allele at rs5751876 are more likely to experience anxiety, sleep disruption, and even panic attacks from caffeine.
  • Those with two copies of the T allele tend to tolerate caffeine better.

Interestingly, chronic caffeine use increases A1 receptor density, leading to tolerance over time. This may explain why some people need more coffee to feel the same effect, while others cut back because they feel worse.

Caffeine, Cardiovascular Risk, and Drug Interactions

  • Heart Attack Risk: Slow metabolizers consuming over 200 mg of caffeine daily (about 2 cups of coffee) have increased cardiovascular risk, while fast metabolizers show reduced risk.
  • Blood Pressure: The CYP1A2 and AHR genes both affect how caffeine influences your blood pressure. Physical activity and smoking status can further modify this risk.
  • Drug Metabolism: The CYP1A2 enzyme also breaks down drugs like clozapine, used to treat schizophrenia. Fast metabolizers may clear the drug too quickly, making treatment less effective.

Should You Get Genetically Tested?

If you rely on caffeine to boost performance or productivity, or if you experience side effects like anxiety, insomnia, or elevated blood pressure, it may be worth testing your CYP1A2, AHR, and ADORA2A genotypes.

  • If you’re a fast metabolizer with low sensitivity, caffeine may enhance performance and protect your cardiovascular system.
  • If you’re a slow metabolizer or sensitive to caffeine, moderation or alternative stimulants may be a better fit.

Personalized nutrition and supplementation strategies are no longer a futuristic idea. Your DNA already holds valuable insights into how you respond to one of the world’s most widely consumed stimulants.

References
  • Guest, N., Corey, P., Vescovi, J., & El-Sohemy, A. (2018). Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes. Medicine & Science in Sports & Exercise, 50, 1570–1578. https://doi.org/10.1249/MSS.0000000000001596.
  • Barreto, G., Esteves, G., Marticorena, F., Oliveira, T., Grgic, J., & Saunders, B. (2023). Caffeine, CYP1A2 Genotype, and Exercise Performance: A Systematic Review and Meta-analysis. Medicine & Science in Sports & Exercise, 56, 328 - 339. https://doi.org/10.1249/MSS.0000000000003313.
  • Barreto, G., Grecco, B., Merola, P., Reis, C., Gualano, B., & Saunders, B. (2021). Novel insights on caffeine supplementation, CYP1A2 genotype, physiological responses and exercise performance. European Journal of Applied Physiology, 121, 749 - 769. https://doi.org/10.1007/s00421-020-04571-7.
  • Grgic, J., Pickering, C., Bishop, D., Schoenfeld, B., Mikulic, P., & Pedišić, Ž. (2020). CYP1A2 genotype and acute effects of caffeine on resistance exercise, jumping, and sprinting performance. Journal of the International Society of Sports Nutrition, 17. https://doi.org/10.1186/s12970-020-00349-6.
  • Grgic, J., Pickering, C., Del Coso, J., Schoenfeld, B., & Mikulic, P. (2020). CYP1A2 genotype and acute ergogenic effects of caffeine intake on exercise performance: a systematic review. European Journal of Nutrition, 60, 1181 - 1195. https://doi.org/10.1007/s00394-020-02427-6.
  • Sun, M., Lyu, L., & Zheng, Q. (2023). Active Binding Modes of Caffeine with Cytochrome P450 1A2 Determine Its Metabolite Profiles.. Chemical research in toxicology. https://doi.org/10.1021/acs.chemrestox.3c00044.
  • Wang, J., Dewi, L., Peng, Y., Hou, C., Song, Y., & Condello, G. (2023). Does ergogenic effect of caffeine supplementation depend on CYP1A2 genotypes? A systematic review with meta-analysis. Journal of Sport and Health Science, 13, 499 - 508. https://doi.org/10.1016/j.jshs.2023.12.005.
  • Salinero, J., Lara, B., Ruiz-Vicente, D., Areces, F., Puente-Torres, C., Gallo-Salazar, C., Pascual, T., & Del Coso, J. (2017). CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study. Nutrients, 9. https://doi.org/10.3390/nu9030269.
  • Puente, C., Abián-Vicén, J., Del Coso, J., Lara, B., & Salinero, J. (2018). The CYP1A2 -163C>A polymorphism does not alter the effects of caffeine on basketball performance. PLoS ONE, 13. https://doi.org/10.1371/journal.pone.0195943.
  • Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999). Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.. British journal of clinical pharmacology, 47 4, 445-9. https://doi.org/10.1046/J.1365-2125.1999.00898.X.
  • (2011). Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption. PLoS Genetics, 7. https://doi.org/10.1371/journal.pgen.1002033.
  • Varillas-Delgado, D., Coso, J., Muñoz, A., Aguilar-Navarro, M., & Gutiérrez-Hellín, J. (2024). Influence of the CYP1A2 c.-163 A > C polymorphism in the effect of caffeine on fat oxidation during exercise: a pilot randomized, double-blind, crossover, placebo-controlled trial.. European journal of nutrition. https://doi.org/10.1007/s00394-024-03454-3.
  • Spineli, H., Pinto, M., Santos, B., Lima-Silva, A., Bertuzzi, R., Gitaí, D., & De Araujo, G. (2020). Caffeine improves various aspects of athletic performance in adolescents independent of their 163 C > A CYP1A2 genotypes. Scandinavian Journal of Medicine & Science in Sports, 30, 1869 - 1877. https://doi.org/10.1111/sms.13749.
  • Guessous, I., Dobrinas, M., Kutalik, Z., Pruijm, M., Ehret, G., Maillard, M., Bergmann, S., Beckmann, J., Cusi, D., Rizzi, F., Cappuccio, F., Cornuz, J., Paccaud, F., Mooser, V., Gaspoz, J., Waeber, G., Burnier, M., Vollenweider, P., Eap, C., & Bochud, M. (2012). Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension.. Human molecular genetics, 21 14, 3283-92. https://doi.org/10.1093/hmg/dds137.
  • Prather, J., Florez, C., Vargas, A., Soto, B., Ross, A., Harrison, A., Secrest, A., Willoughby, D., Kutter, S., & Taylor, L. (2024). Impact of CYP1A2 Genotypes on the Ergogenic Effects and Subjective Mood States of Caffeine Ingestion in Resistance-Trained Women. Nutrients, 16. https://doi.org/10.3390/nu16162767.
  • Soares, R., Schneider, A., Valle, S., & Schenkel, P. (2018). The influence of CYP1A2 genotype in the blood pressure response to caffeine ingestion is affected by physical activity status and caffeine consumption level.. Vascular pharmacology, 106, 67-73. https://doi.org/10.1016/j.vph.2018.03.002.
  • Eugster, H., Probst, M., Würgler, F., & Sengstag, C. (1993). Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae.. Drug metabolism and disposition: the biological fate of chemicals, 21 1, 43-9. https://doi.org/10.1016/s0090-9556(25)07334-9.
  • Anastasiadi, R., Berti, F., Colomban, S., Tavagnacco, C., Navarini, L., & Resmini, M. (2020). Simultaneous Quantification of Antioxidants Paraxanthine and Caffeine in Human Saliva by Electrochemical Sensing for CYP1A2 Phenotyping. Antioxidants, 10. https://doi.org/10.3390/antiox10010010.
  • Lajin, B., Schweighofer, N., Goessler, W., & Obermayer-Pietsch, B. (2021). The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS.. Talanta, 234, 122658. https://doi.org/10.1016/j.talanta.2021.122658.
  • Sachse, C., Bhambra, U., Smith, G., Lightfoot, T., Barrett, J., Scollay, J., Garner, R., Boobis, A., Wolf, C., & Gooderham, N. (2003). Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.. British journal of clinical pharmacology, 55 1, 68-76. https://doi.org/10.1046/J.1365-2125.2003.01733.X.